Adriamycin versus adriamycin plus cis-diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma. A Southwest Oncology Group study

R. Gagliano, H. Levin, M. Nabil El-Bolkainy, H. E. Wilson, R. L. Stephens, W. S. Fletcher, S. E. Rivkin, R. M. O'Bryan, C. A. Coltman, J. H. Saiki, W. J. Stuckey, L. Balducci, J. D. Bonnet, D. O. Dixon

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

Patients with advanced transitional cell bladder carcinoma were randomized to receive either adriamycin alone, or adriamycin plus DDP. Overall response (CR + PR) was 8/41 (19%) for adriamycin alone versus 16/37 (43%) for the combination (p = 0.02). Median response duration was 14 weeks for adriamycin versus 25 weeks for the combination (p = 0.17). Median survival was 28 weeks on adriamycin versus 31 weeks on the combination (p = 0.82). Median survival of responders was 43 weeks, and for patients with stable disease it was 29 weeks. This was significantly better than for those with increasing disease at 15 weeks (p = 0.02). Increased frequency of leukopenia and gastrointestinal toxicity were seen with the combination. Cardiotoxicity and nephrotoxicity were not prohibitive.

Original languageEnglish (US)
Pages (from-to)215-218
Number of pages4
JournalUnknown Journal
Volume6
Issue number2
DOIs
StatePublished - 1983
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Adriamycin versus adriamycin plus cis-diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma. A Southwest Oncology Group study'. Together they form a unique fingerprint.

Cite this